Clinical trials: Asthma, Allergic
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
- Trial name
- NCT05157087
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 16,246 people
- Sponsor
- Novartis Pharmaceuticals
Seasonal Allergic Rhinoconjunctivitis, Asthma
Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma
The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma
- Trial name
- SKY (NCT02761252)
- Testing
- Bilastine 20mg, Montelukast 10mg
- Where
- 32 sites in Croatia, Czechia and 6 more
- Volunteers
- 454 people
- Sponsor
- Menarini International Operations Luxembourg SA
Asthma
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
- Trial name
- NCT00482248
- Testing
- Omalizumab
- Volunteers
- 132 people
- Sponsor
- Novartis
Allergic Rhinoconjunctivitis
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for…
- Trial name
- NCT01567306
- Testing
- Allergovac Depot
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 151 people
- Sponsor
- Roxall Medicina España S.A
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.